0001104659-24-084206.txt : 20240731 0001104659-24-084206.hdr.sgml : 20240731 20240731105433 ACCESSION NUMBER: 0001104659-24-084206 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240731 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240731 DATE AS OF CHANGE: 20240731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entero Therapeutics, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 241160423 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: First Wave BioPharma, Inc. DATE OF NAME CHANGE: 20210921 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 8-K 1 tm2420546d1_8k.htm FORM 8-K
false 0001604191 0001604191 2024-07-31 2024-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 31, 2024

  

  Entero Therapeutics, Inc.  
  (Exact name of registrant as specified in its charter)  

 

Delaware   001-37853   46-4993860
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (IRS Employer Identification No.)

 

777 Yamato Road, Suite 502

Boca Raton, Florida

   33431
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (561) 589-7020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which
registered

Common Stock, par value $0.0001 per share   ENTO   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On July 31, 2024, Entero Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing the issuance of a letter to stockholders from its Chief Executive Officer, James Sapirstein (the “Press Release”). The Press Release is attached hereto as Exhibit 99.1 and is being furnished herewith.

 

The information in this Item 7.01 of this Current Report on Form 8-K (the “Current Report”) and the Press Release being furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the Press Release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

  

99.1* Press Release, dated July 31, 2024
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Furnished herewith

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Entero Therapeutics, Inc.
   
July 31, 2024 By: /s/ James Sapirstein
  Name: James Sapirstein
  Title: Chief Executive Officer

 

 

 

 

 

 

 EX-99.1 2 tm2420546d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

 

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) – Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapirstein, the Company’s Chairman and CEO, to provide stockholders with a business update.

 

LETTER FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER

 

To my fellow stockholders,

 

We are making substantial progress in the development and on the regulatory pathways with our lead product candidate, latiglutenase, a late-stage clinical asset for the treatment of celiac disease. Our primary focus is on advancing latiglutenase into a pivotal Phase 3 trial in 2025. Our recent regulatory agency interactions and operational changes outlined below reflect our sharp focus on positioning Entero for success with this lead program that can potentially address the unmet treatment needs for the millions of people currently struggling with celiac disease.

 

After reviewing previous results from the Phase 2b clinical trial of latiglutenase, we decided to submit two Type D meeting requests to the FDA to build a more precise and efficient Phase 3 clinical trial design and development plan for latiglutenase.

 

The first meeting request seeks approval to change the number of proposed cohorts in the latiglutenase Phase 3 trial from three (600 mg, 1200 mg and placebo) to two (1200 mg and placebo). Since the safety of 1200 mg of latiglutenase has been shown to be comparable to lower doses in previous Phase 2 trials, we believe the higher dose will maximize the efficacy of latiglutenase and provide us with the greatest potential to achieve success in the primary endpoint and key secondary endpoints. This adjustment should reduce the number of patients required for a Phase 3 trial and has the potential to both lower its estimated cost and shorten the time to an interim data read-out and trial completion by several months.

 

We also plan to submit a second Type D meeting request in the next few weeks to finalize our histology-related secondary efficacy endpoints based on previous FDA communications and recent Phase 2 study results demonstrating statistically significant histologic improvements relative to placebo using the highest doses of latiglutenase.

 

 

 

 

Additionally, we are preparing a response to the most recent end of Phase 2 and Type C meeting correspondence with the FDA to propose an updated protocol and streamlined trial design with the single-dose regimen and a focus on the most severe and symptomatic patient population demonstrating intestinal damage. These modifications are designed to expedite and maximize the potential success of the Phase 3 clinical trial.

 

Despite the challenging market conditions affecting all clinical-stage biopharma companies, we completed a small financing that generated $1.9 million in gross proceeds to help support our movement toward initiation of the Phase 3 trial. We have also consolidated our bi-coastal operations into one office at our Boca Raton headquarters. This move streamlines processes, reduces overhead costs and creates a more cohesive work environment, enabling our team to work more efficiently and effectively toward our goals.

 

We thank our stockholders for their continued support and confidence. By focusing our resources and efforts on our most promising program, we are in the strongest position for near-term success, which will serve as a foundation for the advancement of latiglutenase.

 

Sincerely,

 

James Sapirstein

Chairman and CEO

Entero Therapeutics, Inc.

 

About Entero Therapeutics, Inc.

 

Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Entero Therapeutics is headquartered in Boca Raton, Florida. For more information visit www.enterothera.com.

 

 

 

 

Forward-Looking Statements

 

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs, whether any financing or licensing transaction may be obtained, completed in an untimely manner, or not at all; whether the Company will be able to realize the expected benefits of its acquisition of  ImmunogenX; the Company’s ability to integrate the assets and contemplated commercial operations acquired from ImmunogenX into the Company’s  business; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with Nasdaq’s continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; and the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

 

For more information:

Entero Therapeutics, Inc.

777 Yamato Road, Suite 502

Boca Raton, FL 33431

Phone: (561) 589-7020

info@enterothera.com

 

Media contact:

Russo Partners

David Schull or Liz Phillips

(347) 956-7697

david.schull@russopartnersllc.com

elizabeth.phillips@russopartnersllc.com

 

 

 

 EX-101.SCH 3 fwbi-20240731.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fwbi-20240731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fwbi-20240731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2420546d1_ex99-1img001.jpg GRAPHIC begin 644 tm2420546d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 31, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 31, 2024
Entity File Number 001-37853
Entity Registrant Name Entero Therapeutics, Inc.
Entity Central Index Key 0001604191
Entity Tax Identification Number 46-4993860
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 777 Yamato Road
Entity Address, Address Line Two Suite 502
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code 561
Local Phone Number 589-7020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ENTO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://firstwavebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports fwbi-20240731.xsd fwbi-20240731_lab.xml fwbi-20240731_pre.xml tm2420546d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2420546d1_8k.htm": { "nsprefix": "FWBI", "nsuri": "http://firstwavebio.com/20240731", "dts": { "schema": { "local": [ "fwbi-20240731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "fwbi-20240731_lab.xml" ] }, "presentationLink": { "local": [ "fwbi-20240731_pre.xml" ] }, "inline": { "local": [ "tm2420546d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://firstwavebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420546d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420546d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-084206-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-084206-xbrl.zip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end XML 17 tm2420546d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001604191 2024-07-31 2024-07-31 iso4217:USD shares iso4217:USD shares false 0001604191 8-K 2024-07-31 Entero Therapeutics, Inc. DE 001-37853 46-4993860 777 Yamato Road Suite 502 Boca Raton FL 33431 561 589-7020 false false false false Common Stock, par value $0.0001 per share ENTO NASDAQ false